Elranatamab Disease Interactions
There are 3 disease interactions with elranatamab.
Elranatamab (applies to elranatamab) active infection
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Elranatamab can cause serious and fatal infections. Patients should be evaluated for active infection before and during treatment with elranatamab, and administration should be avoided if infection is detected.
Elranatamab (applies to elranatamab) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Elranatamab can cause increased levels of liver enzymes and bilirubin. The effect of moderate to severe hepatic impairment (total bilirubin >1.5 times ULN and any AST) on the pharmacokinetics of elranatamab has not been evaluated.
Elranatamab (applies to elranatamab) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Use elranatamab with caution in patients with severe renal impairment and end-stage renal disease as its effects on its pharmacokinetics have not been studied.
Switch to professional interaction data
Elranatamab drug interactions
There are 401 drug interactions with elranatamab.
Report options
More about elranatamab
- elranatamab consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Darzalex
Darzalex (daratumumab) is a target therapy used to treat multiple myeloma. Includes DARZALEX uses ...
Velcade
Velcade injection is used to treat multiple myeloma and mantle cell lymphoma. Includes Velcade side ...
Pomalyst
Pomalyst (pomalidomide) is used to treat multiple myeloma and AIDS-related Kaposi sarcoma. Includes ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
